Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NoronaPak is a branded **multi-ingredient dietary supplement cocktail** marketed by Apollo Holding as a naturally sourced, pharmacist-curated regimen intended to prepare the body for viral infections and to help suppress flu-like symptoms. Based on the provided sources, the product included multiple common vitamins, supplements, and natural ingredients, with specifically mentioned components including **cannabidiol** and **n-acetylcysteine**; however, the full fixed composition and dosing were not established in the provided material. Its claimed rationale was broad immune support and symptom suppression rather than a defined pharmacologic mechanism against a validated molecular target. Regulatory authorities stated in 2020 that NoronaPak was being marketed with unlawful COVID-19 treatment and prevention claims and that it was an **unapproved drug** under federal law despite being presented as a supplement product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NoronaPak.